CDK4 and small cell lung carcinoma: In addition to the SCLC trials, a randomized, open-label, phase 2 study of trilaciclib prior to gemcitabine and carboplatin (GCb) was performed in patients with metastatic triple-negative breast cancer, predominantly a functionally CDK4/6-independent disease (53).